Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · August 08, 2022

Oral Paclitaxel Plus Encequidar vs Intravenous Paclitaxel in Patients With Metastatic Breast Cancer

Journal of Clinical Oncology

 

Additional Info

Journal of Clinical Oncology
Open-Label, Randomized, Multicenter, Phase III Study Comparing Oral Paclitaxel Plus Encequidar Versus Intravenous Paclitaxel in Patients With Metastatic Breast Cancer
J. Clin. Oncol 2022 Jul 20;[EPub Ahead of Print], HS Rugo, GA Umanzor, FJ Barrios, RH Vasallo, MA Chivalan, S Bejarano, JR Ramírez, L Fein, RD Kowalyszyn, ED Kramer, H Wang, MR Kwan, DL Cutler

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading